PL3036218T3 - Ko-kryształy agomelatyny i kwasu p-toluenosulfonowego, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające - Google Patents

Ko-kryształy agomelatyny i kwasu p-toluenosulfonowego, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające

Info

Publication number
PL3036218T3
PL3036218T3 PL14749937T PL14749937T PL3036218T3 PL 3036218 T3 PL3036218 T3 PL 3036218T3 PL 14749937 T PL14749937 T PL 14749937T PL 14749937 T PL14749937 T PL 14749937T PL 3036218 T3 PL3036218 T3 PL 3036218T3
Authority
PL
Poland
Prior art keywords
same
agomelatine
crystals
pharmaceutical compositions
compositions containing
Prior art date
Application number
PL14749937T
Other languages
English (en)
Inventor
Hanbin Shan
Yuhui SHEN
Ying Luo
Philippe Letellier
Michael Lynch
Original Assignee
Les Laboratoires Servier
Shanghai Institute Of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/080472 external-priority patent/WO2015013903A1/en
Priority claimed from FR1360121A external-priority patent/FR3012141B1/fr
Application filed by Les Laboratoires Servier, Shanghai Institute Of Pharmaceutical Industry filed Critical Les Laboratoires Servier
Publication of PL3036218T3 publication Critical patent/PL3036218T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14749937T 2013-07-31 2014-07-30 Ko-kryształy agomelatyny i kwasu p-toluenosulfonowego, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające PL3036218T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2013/080472 WO2015013903A1 (en) 2013-07-31 2013-07-31 NEW AGOMELATINE p-TOLUENESULFONIC ACID CO-CRYSTAL FORMS AND PREPARATION THEREOF
FR1360121A FR3012141B1 (fr) 2013-10-17 2013-10-17 Nouvelles formes de co-cristaux d'agomelatine et d'acide p-toluenesulfonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2014/051972 WO2015015118A2 (fr) 2013-07-31 2014-07-30 NOUVELLES FORMES DE CO-CRISTAUX D'AGOMELATINE ET D'ACIDE p-TOLUENESULFONIQUE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
EP14749937.0A EP3036218B1 (fr) 2013-07-31 2014-07-30 Co-cristaux d'agomelatine et d'acide p-toluenesulfonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PL3036218T3 true PL3036218T3 (pl) 2019-09-30

Family

ID=51300781

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14749937T PL3036218T3 (pl) 2013-07-31 2014-07-30 Ko-kryształy agomelatyny i kwasu p-toluenosulfonowego, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające

Country Status (24)

Country Link
US (1) US9663451B2 (pl)
EP (1) EP3036218B1 (pl)
JP (1) JP6525996B2 (pl)
AU (1) AU2014298230C1 (pl)
CA (1) CA2918228C (pl)
CY (1) CY1122959T1 (pl)
DK (1) DK3036218T3 (pl)
EA (1) EA031053B1 (pl)
ES (1) ES2734562T3 (pl)
HK (1) HK1223348A1 (pl)
HR (1) HRP20191119T1 (pl)
HU (1) HUE044798T2 (pl)
LT (1) LT3036218T (pl)
ME (1) ME03388B (pl)
MX (1) MX369301B (pl)
NZ (1) NZ716153A (pl)
PL (1) PL3036218T3 (pl)
PT (1) PT3036218T (pl)
RS (1) RS58778B1 (pl)
RU (1) RU2695609C2 (pl)
SG (1) SG11201600005VA (pl)
SI (1) SI3036218T1 (pl)
UA (1) UA117023C2 (pl)
WO (1) WO2015015118A2 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
RS52982B (sr) * 2011-04-28 2014-02-28 Zentiva, K.S. Farmaceutski prihvatljivi kokristali n-[2-(7-metoksi-1-naftil]acetamida i postupci njihove izrade
CN102702041B (zh) * 2012-05-14 2013-08-14 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法
EP2851363B1 (en) 2012-05-14 2018-01-03 Shanghai Righthand Pharmtech. Co., Ltd. Agomelatine acid radical composite, and preparation method and application thereof

Also Published As

Publication number Publication date
AU2014298230A1 (en) 2016-02-04
NZ716153A (en) 2020-08-28
ME03388B (me) 2020-01-20
SG11201600005VA (en) 2016-02-26
RU2695609C2 (ru) 2019-07-24
RS58778B1 (sr) 2019-06-28
HK1222167A1 (zh) 2017-06-23
WO2015015118A3 (fr) 2015-04-02
RU2016106954A3 (pl) 2018-06-01
EA031053B1 (ru) 2018-11-30
DK3036218T3 (da) 2019-07-15
AU2014298230B2 (en) 2018-07-26
EP3036218B1 (fr) 2019-04-10
AU2014298230C1 (en) 2018-11-08
CA2918228A1 (fr) 2015-02-05
LT3036218T (lt) 2019-05-27
HRP20191119T1 (hr) 2019-10-18
US9663451B2 (en) 2017-05-30
EP3036218A2 (fr) 2016-06-29
PT3036218T (pt) 2019-06-11
HUE044798T2 (hu) 2019-11-28
UA117023C2 (uk) 2018-06-11
RU2016106954A (ru) 2017-09-04
CA2918228C (fr) 2019-05-07
EA201600143A1 (ru) 2016-11-30
MX369301B (es) 2019-11-05
JP2016525567A (ja) 2016-08-25
US20160168077A1 (en) 2016-06-16
ES2734562T3 (es) 2019-12-10
MX2016001218A (es) 2016-05-26
HK1223348A1 (zh) 2017-07-28
SI3036218T1 (sl) 2019-06-28
JP6525996B2 (ja) 2019-06-05
CY1122959T1 (el) 2021-10-29
WO2015015118A2 (fr) 2015-02-05

Similar Documents

Publication Publication Date Title
HRP20161202T8 (hr) Novi derivati fosfata, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
HUE045274T2 (hu) Eljárás helyettesített oxiránok és triazolok elõállítására
HUE042516T2 (hu) Javított eljárás treprosztinilnek és származékainak elõállítására
SG11201601363YA (en) Process for purifying an acid composition comprising 2-formyl-furan-5-carboxylic acid and 2,5-furandicarboxylic acid
HUE037498T2 (hu) Új indolizin származékok, elõállítási eljárásuk és ezeket tartalmazó gyógyszerészeti készítmények
ZA201602970B (en) Process for the preparation of iopamidol
IL241038A0 (en) A new salt of abacinostat, a related crystalline form, a method for their preparation and pharmaceutical preparations containing them
IL245474B (en) Process for preparing 5-fluoro-1h-pyrazoles
PT3052466T (pt) Processo para a preparação de xantohumol
GB201323123D0 (en) Method for the preparation of biopolymers
ZA201504691B (en) Novel veterinary pharmaceutical compositions and method for the production thereof
PT3036218T (pt) Novas formas de co-cristais de agomelatina e ácido p-toluenossulfónico, processo para a sua preparação e composições farmacêuticas que as contêm
ME03741B (me) Konpleksi agomelatina i sulfonskih kisjelina, postupak njihove proizvodnje i proizvodnje farmaceutskih pripravaka koji ih sadržavaju
PL2819654T3 (pl) Sposób otrzymywania opartej na modafinilu kompozycji farmaceutycznej, kompozycja farmaceutyczna nim otrzymana i jej zastosowanie
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same